HUP0202703A2 - Poli(ADP-ribóz) polimerázok triciklusos inhibítorai és ezeket tartalmazó gyógyászati készítmények és alkalmazásuk - Google Patents

Poli(ADP-ribóz) polimerázok triciklusos inhibítorai és ezeket tartalmazó gyógyászati készítmények és alkalmazásuk

Info

Publication number
HUP0202703A2
HUP0202703A2 HU0202703A HUP0202703A HUP0202703A2 HU P0202703 A2 HUP0202703 A2 HU P0202703A2 HU 0202703 A HU0202703 A HU 0202703A HU P0202703 A HUP0202703 A HU P0202703A HU P0202703 A2 HUP0202703 A2 HU P0202703A2
Authority
HU
Hungary
Prior art keywords
adp
poly
polymerases
ribose
alkyl
Prior art date
Application number
HU0202703A
Other languages
English (en)
Inventor
Walter Brian Eastman
Robert Arnold Kumpf
Joseph Timothy Marakovits
Donald James Skalitzky
Jayashree Girish Tikhe
Stephen Evan Webber
Original Assignee
Agouron Pharmaceuticals, Inc.
Cancer Research Campaign Technology Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agouron Pharmaceuticals, Inc., Cancer Research Campaign Technology Ltd. filed Critical Agouron Pharmaceuticals, Inc.
Publication of HUP0202703A2 publication Critical patent/HUP0202703A2/hu
Publication of HUP0202703A3 publication Critical patent/HUP0202703A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

A találmány tárgyát képezik az (I) általános képletű vegyületek - ahola szubsztituensek jelentése az alábbiakban megadott - poli(ADP-ribozil) transzferáz inhibitorok. Az ilyen vegyületek gyógyszerekhatóanyagaként rákok kezelésére és gutaütés, fejsérülés vagyneurodegeneratív betegség hatásainak enyhítésére alkalmazhatók. Aszubsztituensek jelentése: X jelentése O vagy S; Y jelentése N vagyCR3; R1 jelentése cianocsoport; szubsztituált alkil- vagy adottesetben szubsztituált alkenil-, alkinil-, cikloalkil-,heerocikloalkil-, aril- vagy heteroarilcsoport; R2 jelentése H vagyalkilcsoport; R4 jelentése H, halogénatom vagy alkilcsoport; R5, R6,R7 és R8 jelentése, egymástól függetlenül H; adott esetbenszubsztituált alkil-, alkenil-, alkinil-, cikloalkil-,heterocikloalkil-, aril- vagy heteroaril-csoport Ó
HU0202703A 1999-08-31 2000-08-31 Tricyclic inhibitors of poly(adp-ribose) polymerases and pharmaceutical compositions containing them and their use HUP0202703A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15214299P 1999-08-31 1999-08-31
PCT/US2000/023882 WO2001016136A2 (en) 1999-08-31 2000-08-31 Tricyclic inhibitors of poly(adp-ribose) polymerases

Publications (2)

Publication Number Publication Date
HUP0202703A2 true HUP0202703A2 (hu) 2002-12-28
HUP0202703A3 HUP0202703A3 (en) 2004-12-28

Family

ID=22541675

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0202703A HUP0202703A3 (en) 1999-08-31 2000-08-31 Tricyclic inhibitors of poly(adp-ribose) polymerases and pharmaceutical compositions containing them and their use

Country Status (48)

Country Link
US (1) US6548494B1 (hu)
EP (1) EP1208104B1 (hu)
JP (1) JP4272375B2 (hu)
KR (1) KR20020038742A (hu)
CN (1) CN1384835A (hu)
AP (1) AP1553A (hu)
AR (1) AR035162A1 (hu)
AT (1) ATE287406T1 (hu)
AU (1) AU781826B2 (hu)
BG (1) BG106562A (hu)
BR (1) BR0015051A (hu)
CA (1) CA2382404C (hu)
CO (1) CO5200769A1 (hu)
CR (1) CR6577A (hu)
CZ (1) CZ2002613A3 (hu)
DE (1) DE60017575T2 (hu)
DK (1) DK1208104T3 (hu)
DO (1) DOP2000000069A (hu)
DZ (1) DZ3216A1 (hu)
EA (1) EA200200306A1 (hu)
EC (1) ECSP003637A (hu)
EE (1) EE200200100A (hu)
ES (1) ES2234657T3 (hu)
GE (1) GEP20043268B (hu)
GT (1) GT200000145A (hu)
HK (1) HK1045509B (hu)
HR (1) HRP20020271A2 (hu)
HU (1) HUP0202703A3 (hu)
IL (1) IL147863A0 (hu)
IS (1) IS6289A (hu)
MA (1) MA25876A1 (hu)
MX (1) MXPA02002138A (hu)
MY (1) MY135910A (hu)
NO (1) NO322475B1 (hu)
NZ (1) NZ516793A (hu)
OA (1) OA12016A (hu)
PA (1) PA8501801A1 (hu)
PE (1) PE20010538A1 (hu)
PL (1) PL354242A1 (hu)
PT (1) PT1208104E (hu)
SI (1) SI1208104T1 (hu)
SK (1) SK2592002A3 (hu)
SV (1) SV2003000162A (hu)
UA (1) UA73144C2 (hu)
UY (1) UY26323A1 (hu)
WO (1) WO2001016136A2 (hu)
YU (1) YU15102A (hu)
ZA (1) ZA200200830B (hu)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6291425B1 (en) 1999-09-01 2001-09-18 Guilford Pharmaceuticals Inc. Compounds, methods and pharmaceutical compositions for treating cellular damage, such as neural or cardiovascular tissue damage
WO2001023390A2 (de) * 1999-09-28 2001-04-05 Basf Aktiengesellschaft Azepinoindol-derivate, deren herstellung und anwendung
DE19946289A1 (de) * 1999-09-28 2001-03-29 Basf Ag Benzodiazepin-Derivate, deren Herstellung und Anwendung
DE10021468A1 (de) * 2000-05-04 2001-11-08 Basf Ag Verwendung von PARP-Inhibitoren in kosmetischen Zubereitungen
US7151102B2 (en) 2000-10-30 2006-12-19 Kudos Pharmaceuticals Limited Phthalazinone derivatives
FR2816942B1 (fr) * 2000-11-23 2003-05-09 Sanofi Synthelabo Derives de benzimidazole, leur preparation et leur application en therapeutique
AU2002358650A1 (en) * 2001-12-14 2003-06-30 Altana Pharma Ag Known and novel 4,5-dihydro-imidazo(4,5,1-ij)quinolin-6-ones useful as poly(adp-ribose)polymerase inhibitors
US7026311B2 (en) 2002-01-10 2006-04-11 Abbott Gmbh & Co., Kg Dibenzodiazepine derivatives, their preparation and use
ES2357057T3 (es) 2002-04-30 2011-04-15 Kudos Pharmaceuticals Limited Derivados de ftalazinona.
AU2003236686A1 (en) * 2002-06-07 2003-12-22 Altana Pharma Ag 4,5-dihydro-imidazo(4,5,1-j) quinolin-6-ones as parp inhibitors
PT1585749E (pt) 2003-01-09 2008-10-23 Pfizer Derivados de diazepinoindole como inibidores de cinase
US7449464B2 (en) 2003-03-12 2008-11-11 Kudos Pharmaceuticals Limited Phthalazinone derivatives
GB0305681D0 (en) 2003-03-12 2003-04-16 Kudos Pharm Ltd Phthalazinone derivatives
PT1660095E (pt) * 2003-07-25 2010-04-19 Pfizer Inibidores tricíclicos de parp
GB0317466D0 (en) 2003-07-25 2003-08-27 Univ Sheffield Use
WO2005035534A1 (ja) * 2003-10-08 2005-04-21 Ono Pharmaceutical Co., Ltd. 複素ビシクロ環および複素トリシクロ環化合物およびその医薬
NZ547984A (en) 2003-12-01 2009-03-31 Kudos Pharm Ltd DNA damage repair inhibitors for treatment of cancer
GB0419072D0 (en) 2004-08-26 2004-09-29 Kudos Pharm Ltd Phthalazinone derivatives
WO2006033003A1 (en) * 2004-09-22 2006-03-30 Pfizer, Inc. Method of preparing poly(adp-ribose) polymerases inhibitors
JP5201995B2 (ja) * 2005-01-19 2013-06-05 エーザイ インク． ジアザベンゾ［デ］アントラセン−３−オン化合物、及び、ｐａｒｐの阻害方法
US7812013B2 (en) 2005-06-14 2010-10-12 Schering Corporation Macrocyclic heterocyclic aspartyl protease inhibitors
EP1908481A1 (en) 2005-06-24 2008-04-09 Ono Pharmaceutical Co., Ltd. Agent for reduction of bleeding in cerebrovascular disorder
RU2447889C2 (ru) * 2005-07-18 2012-04-20 Бипар Сайенсиз, Инк. Способ лечения рака (варианты)
AU2006279034A1 (en) * 2005-08-05 2007-02-15 Astrazeneca Ab Tricyclic benzimidazoles and their use as metabotropic glutamate receptor modulators
GB0521373D0 (en) 2005-10-20 2005-11-30 Kudos Pharm Ltd Pthalazinone derivatives
EP2038654A4 (en) * 2006-06-12 2010-08-11 Bipar Sciences Inc METHOD FOR THE TREATMENT OF DISEASES WITH PARP INHIBITORS
US20100279327A1 (en) * 2006-06-12 2010-11-04 Bipar Sciences, Inc. Method of treating diseases with parp inhibitors
US20080262062A1 (en) * 2006-11-20 2008-10-23 Bipar Sciences, Inc. Method of treating diseases with parp inhibitors
CA2662517A1 (en) * 2006-09-05 2008-03-13 Jerome Moore Treatment of cancer
CA2662337A1 (en) * 2006-09-05 2008-03-13 Bipar Sciences, Inc. Inhibition of fatty acid synthesis by parp inhibitors and methods of treatment thereof
TWI404716B (zh) 2006-10-17 2013-08-11 Kudos Pharm Ltd 酞嗪酮（ｐｈｔｈａｌａｚｉｎｏｎｅ）衍生物
US8188301B2 (en) 2007-06-05 2012-05-29 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Disubstituted phenylpyrrolidines as modulators of cortical catecholaminergic neurotransmission
WO2008154129A1 (en) * 2007-06-08 2008-12-18 Bausch & Lomb Incorporated Pharmaceutical compositions and method for treating, reducing, ameliorating, alleviating, or preventing dry eye
WO2009034326A1 (en) 2007-09-14 2009-03-19 Astrazeneca Ab Phthalazinone derivatives
MX2010005221A (es) * 2007-11-12 2010-09-28 Bipar Sciences Inc Tratamiento de cancer de utero y cancer de ovario con un inhibidor de parp solo o en combinacion con agentes antitumorales.
SG185952A1 (en) * 2007-11-12 2012-12-28 Bipar Sciences Inc Treatment of breast cancer with 4-iodo-3-nitrobenzamide in combination with anti-tumor agents
KR20100102637A (ko) * 2007-12-07 2010-09-24 바이파 사이언스 인코포레이티드 토포이소머라제 억제제 및 ｐａｒｐ 억제제의 병용물에 의한 암의 치료
UY31603A1 (es) 2008-01-23 2009-08-31 Derivados de ftalazinona
AU2009212401A1 (en) * 2008-02-04 2009-08-13 Bipar Sciences, Inc. Methods of diagnosing and treating PARP-mediated diseases
GB0804755D0 (en) * 2008-03-14 2008-04-16 Angeletti P Ist Richerche Bio Therapeutic compounds
DK2346495T4 (da) 2008-10-07 2023-08-28 Kudos Pharm Ltd Farmaceutisk formulering 514
WO2011058367A2 (en) 2009-11-13 2011-05-19 Astrazeneca Ab Diagnostic test for predicting responsiveness to treatment with poly(adp-ribose) polymerase (parp) inhibitor
WO2014037313A1 (de) * 2012-09-05 2014-03-13 Bayer Cropscience Ag Verwendung substituierter benzodiazepinone und benzazepinone oder deren salze als wirkstoffe gegen abiotischen pflanzenstress
CA2935857C (en) * 2014-01-05 2020-12-15 Washington University Radiolabeled tracers for poly (adp-ribose) polymerase-1 (parp-1), methods and uses therefor
SI3325623T1 (sl) 2015-07-23 2019-11-29 Inst Curie Uporaba kombinacije molekule DBAIT in inhibitorjev PARP za zdravljenje raka
GB201519573D0 (en) 2015-11-05 2015-12-23 King S College London Combination
WO2018022851A1 (en) 2016-07-28 2018-02-01 Mitobridge, Inc. Methods of treating acute kidney injury
JP2020500214A (ja) 2016-11-02 2020-01-09 イミュノジェン・インコーポレーテッド 抗体薬物複合体とｐａｒｐ阻害剤との併用治療
WO2018162439A1 (en) 2017-03-08 2018-09-13 Onxeo New predictive biomarker for the sensitivity to a treatment of cancer with a dbait molecule
AU2018260094A1 (en) 2017-04-28 2019-11-07 Akribes Biomedical Gmbh A PARP inhibitor in combination with a glucocorticoid and/or ascorbic acid and/or a protein growth factor for the treatment of impaired wound healing
BR112020013672A2 (pt) 2018-01-05 2020-12-01 Cybrexa 1, Inc. compostos, composições, e métodos para tratamento de doenças que envolvem tecidos afetados por ácidos ou hipoxia
CA3092779A1 (en) 2018-03-13 2019-09-19 Onxeo A dbait molecule against acquired resistance in the treatment of cancer
TW202019408A (zh) * 2018-06-28 2020-06-01 美商永恒生物科技公司 稠合三環雜環化合物及其治療用途
US20240287093A1 (en) * 2018-08-24 2024-08-29 Adlai Nortye Biopharma Co., Ltd. High activity sting protein agonist
CN113195473B (zh) * 2018-12-14 2022-11-22 江苏恒瑞医药股份有限公司 三环化合物作为sting激动剂及其制备方法和医药用途
US20220144850A1 (en) * 2019-02-02 2022-05-12 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Indolo heptamyl oxime analogue as parp inhibitor
CN111909157B (zh) * 2019-05-07 2023-02-03 南京药石科技股份有限公司 Ezh2抑制剂及其用途
JP7675060B2 (ja) 2019-07-10 2025-05-12 サイブレクサ ３，インコーポレイテッド 治療薬としての微小管標的化剤のペプチドコンジュゲート
CA3146560A1 (en) 2019-07-10 2021-01-14 Cybrexa 2, Inc. Peptide conjugates of cytotoxins as therapeutics
GB201913030D0 (en) 2019-09-10 2019-10-23 Francis Crick Institute Ltd Treatment of hr deficient cancer
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
AU2021262569A1 (en) 2020-04-28 2022-11-24 Rhizen Pharmaceuticals Ag Novel compounds useful as poly(ADP-ribose) polymerase (PARP) inhibitors
WO2022090938A1 (en) 2020-10-31 2022-05-05 Rhizen Pharmaceuticals Ag Phthalazinone derivatives useful as parp inhibitors
PE20240119A1 (es) 2021-01-08 2024-01-22 Cybrexa 2 Inc Proceso para preparar un resto enlazador de conjugados
WO2022155172A1 (en) 2021-01-13 2022-07-21 Cybrexa 3, Inc. Peptide conjugates of therapeutics
IL307339A (en) 2021-04-08 2023-11-01 Rhizen Pharmaceuticals Ag Poly(ADP-ribose) polymerase inhibitors
CA3250650A1 (en) * 2022-02-11 2023-08-17 The University Of North Carolina At Chapel Hill ARYLBENZOISOXAZOLE COMPOUNDS USED AS IP6K AND IPMK INHIBITORS AND THEIR METHODS OF USE
WO2024261243A1 (en) 2023-06-21 2024-12-26 Hemispherian As Combination comprising a deoxycytidine derivative and a parp inhibitor for use in a method of treating hr proficient cancer
WO2025106920A1 (en) * 2023-11-15 2025-05-22 Yale University Parp pet imaging agents and methods of using the same

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1052390A (hu) 1964-03-24
US3734919A (en) * 1969-11-03 1973-05-22 Upjohn Co 4,5-di-hydropyrrolo(3,2,1-jk)(1,4)benzodiazepin-7(6h)-ones and 4,5-di-hydropyrrolo(1,2,3-ef)(1,5)benzodiazepin-6(7h)-ones
US3642820A (en) * 1969-11-03 1972-02-15 Upjohn Co 4 5-dihydropyrrolo(3 2 1-jk)(1 4)bezodiazepines
DE2056215A1 (de) 1970-11-16 1972-05-18 Farbwerke Hoechst AG, vorm. Meister Lucius & Brüning, 6000 Frankfurt Verfahren zur Herstellung von N-Mono-(beta-Cyanäthyl>anilinen
US3883590A (en) 1971-06-01 1975-05-13 Universal Oil Prod Co Preparation of n-alkylarylcarboxamides
US3950343A (en) 1973-11-06 1976-04-13 Ayerst, Mckenna And Harrison Ltd. Pyrroloisoquinoline derivatives
US3978066A (en) 1973-11-06 1976-08-31 Ayerst, Mckenna And Harrison Ltd. Certain 4,6-dihydropyrrolotriazoline-quinoline derivatives
US3900477A (en) 1973-11-06 1975-08-19 Ayerst Mckenna & Harrison 5-amino-and 5-hydrazinodihydropyrroloisoquinoline derivatives
JPS57144286A (en) 1981-03-02 1982-09-06 Takeda Chem Ind Ltd Azepinoindole derivative and its preparation
US4910193A (en) 1985-12-16 1990-03-20 Sandoz Ltd. Treatment of gastrointestinal disorders
DE4125292A1 (de) 1991-07-31 1993-02-04 Kali Chemie Pharma Gmbh 6-oxo-azepinoindol-verbindungen sowie verfahren und zwischenprodukte zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
US5342946A (en) 1992-12-02 1994-08-30 Guilford Pharmaceuticals Inc. Phosphonoalkylquinolin-2-ones as novel antagonists of non-NMDA ionotropic excitatory amino acid receptors
CA2150345A1 (en) 1993-09-28 1995-04-06 Makoto Komatsu Quinoxaline derivative as antidiabetic agent
US5587384A (en) 1994-02-04 1996-12-24 The Johns Hopkins University Inhibitors of poly(ADP-ribose) synthetase and use thereof to treat NMDA neurotoxicity
GB9404485D0 (en) 1994-03-09 1994-04-20 Cancer Res Campaign Tech Benzamide analogues
US5561161A (en) 1994-03-25 1996-10-01 Oxigene, Inc. Methods of administering and pharmaceutical formulations containing n-substituted benzamides and/or acid addition salts thereof
US5589483A (en) 1994-12-21 1996-12-31 Geron Corporation Isoquinoline poly (ADP-ribose) polymerase inhibitors to treat skin diseases associated with cellular senescence
ES2105959B1 (es) 1995-01-17 1998-07-01 Zeneca Pharma Sa Derivados de 1,4-dioxido de quinoxalina, procedimiento de preparacion y de utilizacion.
US5756548A (en) 1995-04-03 1998-05-26 Centaur Pharmaceuticals, Inc. Acetamidobenzamide compounds for neurodegenerative disorders
US5659082A (en) 1995-04-03 1997-08-19 Centaur Pharmaceuticals, Inc. Nitro- and aminobenzamide compounds for neurodegenerative disorders
CA2225465A1 (en) * 1995-08-02 1997-02-13 Newcastle University Ventures Limited Benzimidazole compounds
HUT76302A (en) 1995-11-30 1997-07-28 Chinoin Gyogyszer Es Vegyeszet Quinoxaline derivatives, pharmaceutical compositions containing them and process for producing them
GB9702701D0 (en) 1997-02-01 1997-04-02 Univ Newcastle Ventures Ltd Quinazolinone compounds
CN1198614C (zh) 1997-05-13 2005-04-27 奥科特默股份有限公司 pADPRT抑制剂在用于制备治疗炎症和炎性疾病的药物中的方法
US6635642B1 (en) 1997-09-03 2003-10-21 Guilford Pharmaceuticals Inc. PARP inhibitors, pharmaceutical compositions comprising same, and methods of using same
AU9298098A (en) 1997-09-03 1999-03-22 Guilford Pharmaceuticals Inc. Amino-substituted compounds, methods, and compositions for inhibiting parp activity
AU9298198A (en) 1997-09-03 1999-03-22 Guilford Pharmaceuticals Inc. Di-n-heterocyclic compounds, methods, and compositions for inhibiting parp activity
US20020028813A1 (en) 1997-09-03 2002-03-07 Paul F. Jackson Thioalkyl compounds, methods, and compositions for inhibiting parp activity
US20020022636A1 (en) 1997-09-03 2002-02-21 Jia-He Li Oxo-substituted compounds, process of making, and compositions and methods for inhibiting parp activity
US6514983B1 (en) 1997-09-03 2003-02-04 Guilford Pharmaceuticals Inc. Compounds, methods and pharmaceutical compositions for treating neural or cardiovascular tissue damage
US6197785B1 (en) 1997-09-03 2001-03-06 Guilford Pharmaceuticals Inc. Alkoxy-substituted compounds, methods, and compositions for inhibiting PARP activity
JP2002515488A (ja) 1998-05-15 2002-05-28 ギルフォード ファーマシューティカルズ インコーポレイテッド カルボキサミド化合物、組成物、及びｐａｒｐ活性の抑制方法
CA2332239A1 (en) 1998-05-15 1999-11-25 Guilford Pharmaceuticals Inc. Fused tricyclic compounds which inhibit parp activity

Also Published As

Publication number Publication date
GEP20043268B (en) 2004-06-25
HRP20020271A2 (en) 2005-12-31
CO5200769A1 (es) 2002-09-27
AU7338900A (en) 2001-03-26
CZ2002613A3 (cs) 2002-08-14
CN1384835A (zh) 2002-12-11
IS6289A (is) 2002-02-27
ES2234657T3 (es) 2005-07-01
DK1208104T3 (da) 2005-05-02
SI1208104T1 (en) 2005-06-30
NO322475B1 (no) 2006-10-09
UY26323A1 (es) 2001-04-30
AU781826B2 (en) 2005-06-16
PT1208104E (pt) 2005-04-29
DE60017575D1 (de) 2005-02-24
NZ516793A (en) 2004-03-26
ZA200200830B (en) 2003-03-26
CA2382404A1 (en) 2001-03-08
IL147863A0 (en) 2002-08-14
PA8501801A1 (es) 2002-08-26
SK2592002A3 (en) 2002-10-08
EP1208104A2 (en) 2002-05-29
WO2001016136A3 (en) 2001-06-21
MY135910A (en) 2008-07-31
HUP0202703A3 (en) 2004-12-28
BG106562A (bg) 2003-03-31
AP1553A (en) 2006-01-18
ECSP003637A (es) 2002-03-25
DZ3216A1 (fr) 2001-03-08
AR035162A1 (es) 2004-05-05
SV2003000162A (es) 2003-07-29
DE60017575T2 (de) 2005-06-09
YU15102A (sh) 2004-12-31
NO20020421D0 (no) 2002-01-28
ATE287406T1 (de) 2005-02-15
BR0015051A (pt) 2002-06-25
DOP2000000069A (es) 2002-08-30
MA25876A1 (fr) 2003-10-01
OA12016A (en) 2006-04-19
JP4272375B2 (ja) 2009-06-03
EA200200306A1 (ru) 2002-08-29
CR6577A (es) 2003-12-05
EP1208104B1 (en) 2005-01-19
WO2001016136B1 (en) 2001-11-15
CA2382404C (en) 2009-03-24
EE200200100A (et) 2003-06-16
HK1045509B (en) 2005-04-29
MXPA02002138A (es) 2003-08-20
PE20010538A1 (es) 2001-05-22
PL354242A1 (en) 2003-12-29
GT200000145A (es) 2002-02-21
KR20020038742A (ko) 2002-05-23
UA73144C2 (en) 2005-06-15
HK1045509A1 (en) 2002-11-29
NO20020421L (no) 2002-04-25
US6548494B1 (en) 2003-04-15
WO2001016136A2 (en) 2001-03-08
JP2003513015A (ja) 2003-04-08

Similar Documents

Publication Publication Date Title
HUP0202703A2 (hu) Poli(ADP-ribóz) polimerázok triciklusos inhibítorai és ezeket tartalmazó gyógyászati készítmények és alkalmazásuk
HUP0204141A2 (hu) Pirido[2,3-d]pirimidin-2,7-diamin típusú kináz-inhibitorok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
AR017182A1 (es) Compuestos de aminotiazol, inhibidores de las kinasas dependientes de ciclinas y las composiciones farmaceuticas que los contienen.
BR0113838A (pt) Derivados de n-fenil-2-pirimidina-amina
ATE361287T1 (de) Neue indol-2-on derivate
AR023574A1 (es) Compuestos de azepinindol tetraciclico,composiciones farmaceuticas y el uso de dichos compuestos para preparar un medicamento, e intermediarios
IS2114B (is) Kínasólínafleiður til að meðhöndla æxli
HUP0202810A2 (hu) Szubsztituált 2-tio-3.5-diciano-4-aril-6-aminopiridinek és eljárás az előállításukra, valamint ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
SE0102438D0 (sv) New compounds
HUP0303756A2 (hu) 1-Aril- vagy 1-alkilszulfonil-heterociklobenzazolok és eljárás ezek elõállítására és ezeket tartalmazó gyógyszerkészítmények
SE9902987D0 (sv) Novel compounds
SE0202133D0 (sv) Novel compounds
PT1263724E (pt) Novos compostos
BR0014137A (pt) Composto, método para inibir a aurora 2 quinase em um animal de sangue quente, uso de um composto, e, composição farmacêutica
UY27592A1 (es) Nuevo uso
CY1108652T1 (el) Παραγωγα μορφολινυλ-ουριας για χρηση στη θεραπεια φλεγμονωδων ασθενειων
HUP0400246A2 (hu) 1,2,4-Trioxolánt tartalmazó maláriaellenes gyógyszerkészítmények és eljárás az előállításukra és az alkalmazásukra
PA8495101A1 (es) Derivados de 13-metileritromicina
NO20070837L (no) Pyrido-pyrido pyrimidinderivater, fremstilling derav samt terapeutisk anvendelse for behandling av cancer.
SE0302139D0 (sv) Novel compounds
SE9902765D0 (sv) Novel compounds
BG100069A (bg) Амидинови производни,съдържащи хетероциклични групи,получаване и приложението им
HUP0103203A2 (hu) Azaadamantánszármazékok és ezeket tartalmazó gyógyszerkészítmények
ATE401080T1 (de) (3-((chinazolin-4-yl)amino)-1h-pyrazol-1- yl)acetamid derivate und verwandte verbindungen als aurora kinase inhibitoren zur behandlung von proliferativen erkrankungen wie krebs
SE0300456D0 (sv) Novel compounds

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees